AbbVie (NY:ABBV)

262.21 -0.61 (-0.23%)

Delayed Quote Updated: 11:09 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

The Smartest Dividend Stocks to Buy With $300 Right Now ↗

July 12, 2025

Via The Motley Fool

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades' ↗

July 11, 2025

The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential...

Via Benzinga

How Is The Market Feeling About AbbVie? ↗

June 11, 2025

Via Benzinga

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill ↗

July 11, 2025

A steady dose of quality companies will keep your portfolio growing big and strong.

Via The Motley Fool

Topics Intellectual Property

AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers ↗

July 10, 2025

Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China.

Via Stocktwits

Topics Product Recall

Why Is AbbVie Stock Trading Higher On Thursday? ↗

July 10, 2025

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.

Via Benzinga

Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together' ↗

July 08, 2025

Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.

Via Stocktwits

Topics ETFs Economy Government

3 No-Brainer Stocks to Buy in July ↗

July 07, 2025

Via The Motley Fool

2 Dividend Stocks to Buy for Decades of Passive Income ↗

July 06, 2025

Via The Motley Fool

Topics Intellectual Property

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

July 05, 2025

Via The Motley Fool

Topics Economy Intellectual Property

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial ↗

July 03, 2025

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.

Via Benzinga

3 Profitable Stocks Skating on Thin Ice

July 03, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

July 01, 2025

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade ↗

June 30, 2025

The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases.

Via Stocktwits

Topics Intellectual Property

3 Dividend Stocks to Double Up on Right Now ↗

June 29, 2025

Via The Motley Fool

Topics Government World Trade

Got $500? 2 Healthcare Stocks to Buy and Hold Forever ↗

June 28, 2025

Via The Motley Fool

Topics Artificial Intelligence

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗

June 26, 2025

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Via Investor's Business Daily

Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere ↗

June 20, 2025

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

Via Benzinga

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.

Via Benzinga

AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial ↗

June 18, 2025

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Via Benzinga

AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail Cheer ↗

June 18, 2025

Atogepant had fewer discontinuations in the study involving 545 participants due to adverse events than Topiramate.

Via Stocktwits

Topics Economy

AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine ↗

June 17, 2025

Via Benzinga

Topics Artificial Intelligence Initial Public Offering

Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills ↗

June 17, 2025

The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such...

Via Stocktwits

Topics Government

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes ↗

June 17, 2025

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

Via Benzinga

Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood ↗

June 16, 2025

The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.

Via Stocktwits

AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence ↗

June 16, 2025

The company stated that no safety signals were observed in the study comparing the efficacy and safety of Venetoclax in combination with Azacitidine compared to Azacitidine and placebo in the treatment...

Via Stocktwits

1 Cash-Producing Stock for Long-Term Investors and 2 to Steer Clear Of

June 16, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

AbbVie Stock Rises After FDA Approves Expanded Treatment Scope For Mavyret, But Retail Needs More To Cheer ↗

June 11, 2025

The approval makes Mavyret the first and only oral eight-week direct-acting antiviral therapy for people with Acute Hepatitis C Virus.

Via Stocktwits

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.